Tigris Pharmaceuticals, Inc., announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 (aminoflavone prodrug) with or without Faslodex� (fulvestrant) in estrogen receptor (ER)-positive breast cancer patients. Molecular profiling will be used to pre-screen patients for a biomarker called Aryl Hydrocarbon Receptor (AhR), which has shown to predict sensitivity to AFP-464. It is estimated that approximately 70 percent of breast cancers are ER-positive (1)...
No comments:
Post a Comment